The difference in biological properties between parental and v-Ha-ras transformed NIH3T3 cells.
OBJECTIVE
We performed experiments to investigate the change in cellular signaling that occurs during the transformation of a normal cell to a cell capable of cancerous growth, and we did so by using the NIH 3T3 cells that were transformed by transfection with the v-Ha-ras oncogene.


METHODS
Parental and v-Ha-ras transfected NIH 3T3 cells were chosen as test systems. The siRNA transfections were performed using Lipofectamine 2000. The cell proliferation reagent WST-1 was used for the quantitative determination of cellular proliferation. Immunoblot analysis was performed using the ECL-Plus chemiluminescent system and a KODAK Image Station 4000R.


RESULTS
The v-Ha-ras-transformed cells were found to be significantly more resistant to PP2 treatment, which is a potent inhibitor of the Src family tyrosine kinases, than were the parental cells at earlier times after treatment. However, PP2 induced growth arrest and the senescence-like phenotypes in both cell lines after longer treatment. Furthermore, the Raf-1 kinase of the v-Ha-ras-transformed cells was not affected by the expressed level of Sprouty proteins, which are negative regulators of the MAPK pathway, as evidenced by the failure of siRNA-mediated knockdown of Spry4 to activate Raf-1 kinase. Dephostatin (a tyrosine phosphatase inhibitor) effectively inhibited the proliferation of the v-Ha-ras transformed cells, whereas dephostatin had only a small effect on the parental cells' proliferation. This implied an inhibitory role for tyrosine phosphatase that is specific to the signaling pathway in the v-Ha-ras transformed cells.


CONCLUSIONS
Taken together, our results show that the sustained activation of the oncogenic pathways through their resistance to negative feedback regulation might contribute to the transformation of NIH 3T3 cells.
Lee
Michael
M
Department of Biology, College of Natural Sciences, University of Incheon, Incheon, Korea. mikelee@incheon.ac.kr
Ahn
Jun-Ho
JH
Eum
Ki-Hwan
KH
EMBO Rep. 2005 Mar;6(3):251-5
15711535
EMBO J. 1995 Jul 3;14(13):3136-45
7542586
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2922-6
1372995
J Biol Chem. 1999 Mar 19;274(12):7936-40
10075689
Nat Rev Mol Cell Biol. 2004 Jun;5(6):441-50
15173823
Mol Cell Biol. 2003 Jan;23(2):543-54
12509453
Curr Biol. 2001 Apr 17;11(8):614-9
11369207
J Biol Chem. 2004 Nov 19;279(47):48692-701
15356004
FASEB J. 1995 Oct;9(13):1311-8
7557021
Biochem Biophys Res Commun. 2003 Nov 28;311(4):1026-33
14623285
Mol Cell Biol. 2005 Aug;25(15):6391-403
16024778
Cell. 1997 Mar 7;88(5):593-602
9054499
Biochem Biophys Res Commun. 2006 Nov 17;350(2):450-6
17010316
Adv Cancer Res. 1992;58:53-73
1312290
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5772-6
8390681
J Clin Invest. 1998 Jan 1;101(1):153-9
9421477
FEBS J. 2008 Jan;275(1):69-88
18067579
Proc Natl Acad Sci U S A. 1983 Jul;80(14):4218-22
6308607
J Biol Chem. 1996 Jan 12;271(2):695-701
8557675
Tumori. 1995 May-Jun;81(3 Suppl):7-11
7571058
Curr Opin Cell Biol. 1996 Apr;8(2):197-204
8791426
Nature. 2003 Jun 12;423(6941):769-73
12802338
J Biol Chem. 2002 Feb 1;277(5):3195-201
11698404
Nat Cell Biol. 2003 May;5(5):427-32
12717443
Br J Cancer. 1995 Jul;72(1):123-8
7599040